Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aclaris TherapeuticsLTS:0H8T +1.75%36 Cyclically Adjusted PB Ratio is 1.50 as of Aug. 18, 2026, which is 200% above its 10-year median of 0.50. GuruFocus rates LTS:0H8T with a GF Score™ of 36/100 and a GF Value™ of $0.42 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 693 Biotechnology companies, Aclaris Therapeutics ranks better than 52.53% on this metric.
The historical rank and industry rank for Aclaris Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
LTS:0H8T'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.26 Med: 0.5 Max: 1.51
Current: 1.48
During the past years, Aclaris Therapeutics's highest Cyclically Adjusted PB Ratio was 1.51. The lowest was 0.26. And the median was 0.50.
LTS:0H8T's Cyclically Adjusted PB Ratio is ranked better than 52.53% of 693
companies
in the Biotechnology industry
Industry Median: 1.63
vs LTS:0H8T: 1.48
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Aclaris Therapeutics's adjusted book value per share data for the three months ended in Jun. 2026 was $0.891. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.89 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Aclaris Therapeutics (LTS:0H8T) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Aclaris Therapeutics Cyclically Adjusted PB Ratio Related Terms
Aclaris Therapeutics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Aclaris Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics Cyclically Adjusted PB Ratio Chart
LTS:0H8T vs FTH, AURA, CLYM: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Aclaris Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's Cyclically Adjusted PB Ratio falls into.
Aclaris Therapeutics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.50 mean?
Aclaris Therapeutics (LTS:0H8T) has a Cyclically Adjusted PB Ratio of 1.50 as of Aug. 18, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors. This is 200% above median its historical median of 0.50. Over the past decade, Aclaris Therapeutics' Cyclically Adjusted PB Ratio has ranged from 0.26 to 1.51. According to the industry distribution chart, Aclaris Therapeutics ranks #329 out of 693 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Aclaris Therapeutics' Cyclically Adjusted PB Ratio too high?
Aclaris Therapeutics' current Cyclically Adjusted PB Ratio of 1.50 is 200% above median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 1.51. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.63. Aclaris Therapeutics' value of 1.50 is 8% below this industry median. Based on the distribution chart, Aclaris Therapeutics ranks #329 out of 693 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aclaris Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' Cyclically Adjusted PB Ratio compare to FTH and AURA?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #329 out of 693 companies for Cyclically Adjusted PB Ratio. This puts Aclaris Therapeutics in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.63. Aclaris Therapeutics' value of 1.50 is 8% below this benchmark. Historically, Aclaris Therapeutics' own Cyclically Adjusted PB Ratio has ranged from 0.26 to 1.51 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 1.63, Aclaris Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.63, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aclaris Therapeutics's current Cyclically Adjusted PB Ratio of 1.50 is 8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Aclaris Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclaris Therapeutics's current Cyclically Adjusted PB Ratio is 1.50, which is 200% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (LTS:0H8T) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.42, compared to a current price of $5.82 — trading 1285.7% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 1.50, which is 200% above median its 10-year median of 0.50 and 8% below the Biotechnology industry median of 1.63. Aclaris Therapeutics' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Aclaris Therapeutics (LTS:0H8T), the current Cyclically Adjusted PB Ratio is 1.50 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aclaris Therapeutics (LTS:0H8T) Overvalued in 2026?
Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued.
The current stock price of $5.82 is trading 1285.7% above its estimated GF Value™ of $0.42.
GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.
Key valuation signals for LTS:0H8T:
Cyclically Adjusted PB Ratio: 1.50 (200% above median its 10-year median of 0.50)
GF Value™: $0.42 vs. price of $5.82 (1285.7% above fair value)
Industry Position: 8% below the Biotechnology median (#329 of 693)
No single metric tells the full story. See the LTS:0H8T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
36GF Score
Get the complete analysis for LTS:0H8T
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0H8T has been successfully added to your 
